Comparison of 0.4 Hyaluronic Acid Solution Versus Hydroxyethylamide Solution in Submucosal Endoscopic Resections of Superficial Malignant Esophageal Neoplasms

What this Trial Is About

Researchers are evaluating the effectiveness of two different solutions used during the submucosal cushion formation stage of endoscopic submucosal resections for early esophageal malignant tumors. This randomized clinical trial is conducted at a single center and aims to compare 0.4 hyaluronic acid solution TS-905 Blue Eye and hydroxyethylamide solution in treating patients with early esophageal neoplasia. Patients are grouped based on the size of their lesions to ensure balanced comparison. Participants will undergo submucosal endoscopic dissection using either hydroxyethylamide or hyaluronic acid solution. Both procedures involve three stages delimitation, incision, and dissection. The chosen solution is injected to create a cushion under the lesion, followed by careful cutting around the lesion with specialized equipment. There are two treatment groups, each including 15 patients receiving one of the solutions during their procedure. During the study, researchers will measure the volume of solution used, the duration of the procedure, and the number of additional injections needed. The main goal is to determine which solution better supports complete lesion removal with fewer injections. Participants will be monitored during the procedure, and the study is expected to continue until April 2026, ensuring careful assessment of treatment outcomes and safety throughout the process.

Comparison of 0.4% Hyaluronic Acid Solution Versus Hydroxyethylamide Solution in Submucosal Endoscopic Resections